Delhi, 21 July (H.S.): Anthem Biosciences, a biotech firm servicing large pharmaceutical companies, made a notable stock market debut today, thrilling IPO investors. Its shares were initially priced at ₹570 and opened at ₹723.10 on the BSE and ₹723.05 on the NSE, marking a nearly 26 percent gain at listing. Following this, buying activity drove shares to the upper circuit level of ₹734.82, resulting in a profit of 28.91 percent for IPO investors on the first trading day.
The company's IPO, worth ₹3,395.79 crore, was open for subscription from July 14 to 16, receiving an overwhelming response with a subscription rate of 67.42 times. Qualified Institutional Buyers (QIB) subscribed 192.80 times, Non-Institutional Investors (NII) 44.70 times, retail investors 5.98 times, and employee shares 6.99 times. No new shares were issued; instead, 5,95,75,319 shares were sold via the offer-for-sale window. Financially, the company reported a net profit of ₹385.19 crore for fiscal year 2022-23, projected to grow to ₹451.26 crore by 2024-25, with a revenue CAGR exceeding 30 percent.
---------------
Hindusthan Samachar / Jun Sarkar
